What was the market valuation of the US generic injectables market in 2024?

The market valuation was $4550.0 Million in 2024. Read More

What is the projected market valuation for the US generic injectables market by 2035?

The projected valuation for 2035 is $13460.0 Million. Read More

What is the expected CAGR for the US generic injectables market during the forecast period 2025 - 2035?

The expected CAGR is 10.36% during the forecast period 2025 - 2035. Read More

What are the main formulation types in the US generic injectables market and their valuations?

Formulation types include Solution ($4098.0 Million), Suspension ($2730.0 Million), Emulsion ($2047.5 Million), and Lyophilized ($4784.5 Million). Read More

What routes of administration are prevalent in the US generic injectables market?

Prevalent routes include Intravenous ($5460.0 Million), Intramuscular ($2730.0 Million), Subcutaneous ($2730.0 Million), and Intradermal ($2730.0 Million). Read More

Which therapeutic areas are driving growth in the US generic injectables market?

Driving therapeutic areas include Oncology ($2400.0 Million), Cardiovascular ($1800.0 Million), Infectious Diseases ($1500.0 Million), and Hormonal Disorders ($1200.0 Million). Read More

What packaging types are utilized in the US generic injectables market?

Utilized packaging types include Vials ($4500.0 Million), Ampoules ($3000.0 Million), Pre-filled Syringes ($3600.0 Million), and Bags ($2600.0 Million). Read More

How does the market performance of Solution compare to other formulation types?

Solution leads with a valuation of $4098.0 Million, surpassing other formulation types like Suspension and Emulsion. Read More

What trends are anticipated in the US generic injectables market by 2035?

Trends may include increased market valuation and expansion in therapeutic areas, driven by a CAGR of 10.36%. Read More

US Generic Injectables Market

Q: Which companies are considered key players in the US generic injectables market?

Key players include Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Mylan N.V., and Fresenius Kabi AG. Read More

ID: MRFR/HC/11480-CR 100 Pages Rahul Gotadki Last Updated: September 15, 2026

US Generic Injectables Market Research Report: Size, Share, Trend Analysis By Product Type (Monoclonal antibodies, Cytokines, Insulin, Vaccines), Container (Vials, Ampoules, Premix, Prefilled syringes), Application (Oncology, Anaesthesia, Anti-infectives, Cardiovascular), Distribution Channel (Hospital pharmacy, Retail pharmacy, Drug stores, Online stores) – Forecast Till 2035

US Generic Injectables Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)10.36%

2024 Market Size$ 4,550 Million

2025 Market Size$ 5,021.38 Million

2035 Market Size$ 13,460 Million

Key Players

Teva Pharmaceutical Industries Ltd

Sandoz International GmbH

Mylan N.V.

Fresenius Kabi AG

Baxter International Inc

Amgen Inc

Trends

Rising Demand for Cost-Effective Solutions
Regulatory Support for Market Entry
Technological Advancements in Manufacturing

Opportunities

Expansion of Biosimilars
Focus on Preventive Healthcare
Increasing Healthcare Expenditure

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Security, Access Control and Robotics, BY Formulation Type (USD Million)
  1. 4.1.1 Solution
  2. 4.1.2 Suspension
  3. 4.1.3 Emulsion
  4. 4.1.4 Lyophilized
2. 4.2 Security, Access Control and Robotics, BY Route of Administration (USD Million)
  1. 4.2.1 Intravenous
  2. 4.2.2 Intramuscular
  3. 4.2.3 Subcutaneous
  4. 4.2.4 Intradermal
3. 4.3 Security, Access Control and Robotics, BY Therapeutic Area (USD Million)
  1. 4.3.1 Oncology
  2. 4.3.2 Cardiovascular
  3. 4.3.3 Infectious Diseases
  4. 4.3.4 Hormonal Disorders
4. 4.4 Security, Access Control and Robotics, BY Packaging Type (USD Million)
  1. 4.4.1 Vials
  2. 4.4.2 Ampoules
  3. 4.4.3 Pre-filled Syringes
  4. 4.4.4 Bags
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Sandoz International GmbH (AT)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Mylan N.V. (NL)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Fresenius Kabi AG (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Baxter International Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Amgen Inc (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Hospira Inc (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Zydus Cadila (IN)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Aurobindo Pharma (IN)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY FORMULATION TYPE
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY THERAPEUTIC AREA
5. 6.5 US MARKET ANALYSIS BY PACKAGING TYPE
6. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
9. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
11. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY FORMULATION TYPE, 2024 (% SHARE)
13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY FORMULATION TYPE, 2024 TO 2035 (USD Million)
14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY THERAPEUTIC AREA, 2024 (% SHARE)
17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PACKAGING TYPE, 2024 (% SHARE)
19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PACKAGING TYPE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY FORMULATION TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
  4. 7.2.4 BY PACKAGING TYPE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

US Generic Injectables Market Segmentation

US Generic Injectables Market By Formulation Type (USD Million, 2025-2035)

Solution
Suspension
Emulsion
Lyophilized

US Generic Injectables Market By Route of Administration (USD Million, 2025-2035)

Intravenous
Intramuscular
Subcutaneous
Intradermal

US Generic Injectables Market By Therapeutic Area (USD Million, 2025-2035)

Oncology
Cardiovascular
Infectious Diseases
Hormonal Disorders

US Generic Injectables Market By Packaging Type (USD Million, 2025-2035)

Vials
Ampoules
Pre-filled Syringes
Bags

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”